Purpose 18F-DOPA PET/CT is potentially helpful in the management of patients with low-grade brain tumors, movement disorders, and somatic neuroendocrine tumors. We describe the whole-body physiological distribution of 18F-DOPA uptake. Patients and Methods We examined 215 patients with 18F-DOPA PET/CT. Among these, 161 had brain scans and 54 had whole-body scans. Results Physiological distribution was negligible in the brain, with the exception of basal ganglia, whereas greatest activity was noted in the liver, pancreas, other exocrine glands, and the urinary system. Incidental tracer uptake sites were identified in 5.5% of patients. Some of these findings were due to inflammation, whereas in most cases, uptake was seen in benign tumors of the brain or in the endocrine or exocrine glands. Conclusions 18F-DOPA uptake may be seen in inflammatory tissue or benign tumors. Correlations with history, physical examination, laboratory examination, CT, MRI, and histology are necessary for optimal diagnosis.

18F-dopa pet/ct physiological distribution and pitfalls: experience in 215 patients / Calabria, F. F.; Chiaravalloti, A.; Jaffrain-Rea, M. L.; Zinzi, M.; Sannino, P.; Minniti, G.; Rubello, D.; Schillaci, O.. - In: CLINICAL NUCLEAR MEDICINE. - ISSN 0363-9762. - 41:10(2016), pp. 753-760. [10.1097/RLU.0000000000001318]

18F-dopa pet/ct physiological distribution and pitfalls: experience in 215 patients

Minniti G.;
2016

Abstract

Purpose 18F-DOPA PET/CT is potentially helpful in the management of patients with low-grade brain tumors, movement disorders, and somatic neuroendocrine tumors. We describe the whole-body physiological distribution of 18F-DOPA uptake. Patients and Methods We examined 215 patients with 18F-DOPA PET/CT. Among these, 161 had brain scans and 54 had whole-body scans. Results Physiological distribution was negligible in the brain, with the exception of basal ganglia, whereas greatest activity was noted in the liver, pancreas, other exocrine glands, and the urinary system. Incidental tracer uptake sites were identified in 5.5% of patients. Some of these findings were due to inflammation, whereas in most cases, uptake was seen in benign tumors of the brain or in the endocrine or exocrine glands. Conclusions 18F-DOPA uptake may be seen in inflammatory tissue or benign tumors. Correlations with history, physical examination, laboratory examination, CT, MRI, and histology are necessary for optimal diagnosis.
2016
18; F-DOPA; brain tumor; molecular imaging; PET/CT; pitfalls
01 Pubblicazione su rivista::01a Articolo in rivista
18F-dopa pet/ct physiological distribution and pitfalls: experience in 215 patients / Calabria, F. F.; Chiaravalloti, A.; Jaffrain-Rea, M. L.; Zinzi, M.; Sannino, P.; Minniti, G.; Rubello, D.; Schillaci, O.. - In: CLINICAL NUCLEAR MEDICINE. - ISSN 0363-9762. - 41:10(2016), pp. 753-760. [10.1097/RLU.0000000000001318]
File allegati a questo prodotto
File Dimensione Formato  
Calabria_18F-Dopa pet_2016.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 4.35 MB
Formato Adobe PDF
4.35 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1676366
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 24
social impact